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Purpose: The aim of this study was to determine the long-term safety of drug-eluting stent 
(DES) versus bare metal stent (BMS) implantation in a “real-world” setting.
Patients and methods: A total of 1809 patients who were treated with implantation of either 
BMS or DES were assessed. Kaplan-Meier and multivariate Cox regression analyses concerning 
primary endpoint of cardiac mortality were performed.
Results: A total of 609 patients received DES. Mean age was 66.2 ± 11.3 years, 69.4% were 
male, and 1517 (83.8%) were treated for acute coronary syndrome (unstable angina 510 [28.2%], 
non-ST-elevation myocardial infarction [NSTEMI] 506 [28.0%], and ST-elevation myocardial 
infarction [STEMI] 501 [27.7%]). Mean follow-up was 34 ± 15 months. During follow-up, 
268 patients died of cardiac causes (DES 42 [7.3%]; BMS 226 [19.6%]; P , 0.001).   Univariate 
Kaplan-Meier analysis showed an advantage of DES over BMS concerning the primary end-
point (P , 0.001). When adjusting for classic risk factors and additional factors that affect the 
progression of coronary heart disease (CHD), DES was not found to be superior to BMS (hazard 
ratio 0.996, 95% confidence interval 0.455–2.182, P = 0.993). Severely impaired renal function 
was an independent predictor for cardiac mortality after stent implantation.
Conclusion: Treatment with DES is safe in the long term, also in patients presenting with 
STEMI. However, in multivariate analyses it is not superior to BMS treatment.
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Introduction
Stent implantation has been established as a safe and effective method of treating 
coronary heart disease (CHD).1,2 Several clinical trials investigating the safety and 
efficacy of drug-eluting stents (DES) versus bare metal stents (BMS) showed an 
advantage of DES over BMS concerning restenosis.3–5 Since being introduced into 
clinical practice in 2003, DES have been increasingly used in patients with stable and 
unstable CHD.6
Late stent thrombosis as a fatal event 12 or more months after DES implantation is 
associated with a mortality of up to 45%7,8 and represents a major concern.   Therefore, 
the long-term safety of DES has been extensively discussed in the past several years. 
Various authors reported an increasing incidence of cardiac death related to DES 
implantation.9–11 One of the main reasons for the increase in cardiac and cardiovas-
cular mortality after DES treatment seems to be the fact that patient populations in 
these trials are highly selected and, thus, applying the findings to “real-world” use 
has limitations.
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The aim of this study, therefore, was to determine the safety 
of DES versus BMS implantation in a “real-world” setting.
Patients and methods
Patients, demographic, clinical,  
and angiographic data
A total of 2056 CHD patients in whom a percutaneous 
coronary intervention (PCI) was performed with implanta-
tion of a BMS or DES at the Department of Medicine III, 
Martin Luther-University Halle-Wittenberg between 2004 
and 2006 were retrospectively assessed. Inclusion criterion 
was the implantation of a DES or BMS. Exclusion criteria 
included balloon dilatation without stent implantation or 
unsuccessful PCI and the decision for solely medical treat-
ment. The choice of stent type was up to the interventional 
cardiologist based on national and international guidelines 
and   recommendations. Thus, DES were more frequently 
used in patients with stable or unstable angina in native 
vessels, whereas BMS were more frequently implanted in 
patients presenting with acute myocardial infarction and 
more complicated lesions (ie, bifurcational or ostial lesions, 
unprotected left main).7 In case a patient received both stent 
types during the hospital stay, she/he was assigned to the 
drug-eluting stent cohort. PCI during a prior hospital stay 
was not considered in this analysis.
Data were collected concerning admission diagnosis 
  (stable angina [SAP], unstable angina [UAP], non-ST-
  elevation myocardial infarction [NSTEMI], ST-elevation 
myocardial infarction [STEMI]), bodyweight, height, 
medical history, classic risk factors (family history of CHD, 
diabetes mellitus, hyperlipidemia, hypertension, and current 
smoking), history of transient ischemic attacks (TIA) or 
stroke, current medication, duration of hospital stay, labo-
ratory test results, and angiographic data. Left ventricular 
ejection fraction was measured by routinely performed 
echocardiography.
In-hospital adverse events included cardiac and 
noncardiac death, myocardial infarction, stroke/TIA, re-
PCI, operative revascularization, and acute renal failure. 
  Bleeding complications were recorded as puncture site 
bleeding, hematoma, aneurysm, arteriovenous fistula, 
gastrointestinal bleeding, intracranial bleeding, and minor 
bleeding complications (not related to puncture site, eg,   
epistaxis).
Primary endpoint was death from cardiac causes. This 
information was (as described in the following) obtained 
from electronic patient files, physicians, relatives, and civil 
registration offices.
Follow-up
For acquiring follow-up data a standardized questionnaire 
was sent out, which included questions concerning adverse 
events such as hospital admission, re-PCI or surgical 
coronary revascularization, bleeding complications, and 
thromboembolic events. If the patients did not send back the 
questionnaires, a telephone interview was conducted with 
the patient or his/her relatives or the patient’s physician was 
contacted. If this information could not be obtained from 
these persons, civil registration offices were contacted and 
information was requested about current address or date of 
death. The study was approved by the ethics committee of 
the Martin Luther-University Halle-Wittenberg.
Statistical analyses
Continuous variables were described as mean and standard 
deviation; skewed variables as median and 25% and 75% 
quartiles. Categorical variables were documented as a 
  percentage. For comparison of metric, normally distributed 
variables, t-test was used. Mann-Whitney U-test was used 
to compare skewed variables. For normally distributed, 
  categorical variables, the chi-square test was employed. 
  Survival analyses included Kaplan-Meier analyses with 
log-rank test and multivariate Cox regression analyses. 
  Multivariate Cox regression was applied to analyze the influ-
ence of DES on the primary endpoint, which included the 
classic risk factors (gender, body mass index, current smoking, 
diabetes mellitus, hypertension, hyperlipidemia, and family 
history of CHD) and additional factors affecting prognosis 
after stent implantation (age, hemoglobin, C-reactive protein, 
low density lipoprotein [LDL] cholesterol, glomerular filtra-
tion rate, and left ventricular ejection fraction).
P-values ,0.05 were considered significant. Statistical 
analyses were performed using SPSS Statistics (SPSS Inc, 
Chicago, IL) software.
Results
Patient characteristics
Of the 2056 patients, 1809 individuals met the inclusion 
criteria: 609 patients received DES, and 1200 received BMS. 
At the time of admission to the hospital, the mean age was 
66.2 ± 11.3 years; patients treated with DES were signifi-
cantly younger than patients treated with BMS (60.9 ± 11.4 
versus 68.9 ± 10.2 years, P , 0.001). Of the patients, 69.4% 
were male (73.6% in the DES group versus 67.2% in the 
BMS group (P = 0.007) (Table 1).
The two groups also differed significantly regarding 
other cardiovascular risk factors: the prevalence of diabetes 
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Table 1 Baseline characteristics, admission diagnosis, and number of diseased vessels
Variable (n = 1809) DES (n = 609) BMS (n = 1200) P-value
Age, mean (SD) 66.2 (±11.3) 60.9 (±11.4) 68.9 (±10.2) ,0.001
Male, n (%) 1255 (69.4) 448 (73.6) 807 (67.2) 0.007
Medical history, n (%)
  Current smoker 410 (22.8) 169 (27.8) 241 (20.2) ,0.001
  Diabetes mellitus 631 (35.0) 168 (27.6) 463 (38.6) ,0.001
  Hypertension 1312 (72.5) 422 (69.3) 890 (74.2) 0.020
  Hyperlipidemia 657 (36.3) 249 (40.9) 408 (34.0) 0.005
  Family history 392 (21.7) 183 (30.0) 209 (17.4) ,0.001
  Coronary heart disease 655 (36.1) 230 (37.8) 425 (35.4) 0.326
  Peripheral artery disease 137 (7.6) 37 (6.1) 100 (8.4) 0.087
  Myocardial infarction 400 (22.1) 127 (20.9) 273 (22.8) 0.358
  Previous PCI 321 (17.7) 118 (19.4) 203 (16.9) 0.193
Ejection fraction, mean (SD) 54 (±15) 58 (±15) 52 (±16) ,0.001
BMI, mean (SD) 28.2 (4.5) 28.0 (4.6) 28.2 (4.5) 0.389
Admission diagnosis, n (%)
  SAP 258 (14.3) 121 (19.9) 137 (11.4) ,0.001
  UAP 510 (28.2) 198 (32.5) 312 (26.0) 0.003
  nSTEMI 506 (28.0) 154 (25.3) 352 (29.3) 0.058
  STEMI 501 (27.7) 126 (20.7) 375 (31.2) ,0.001
  Other 34 (1.9) 10 (1.6) 24 (2.0) 0.394
n vessel disease, n (%)
 1 402 (22.2) 157 (25.8) 245 (20.4) 0.006
 2 579 (32.0) 194 (31.9) 385 (32.1) 0.939
 3 828 (45.8) 256 (42.0) 572 (47.7) 0.028
  GFR, mL/min 76 (56/101) 90 (66/112) 70 (52/94) ,0.001
  LDL cholesterol, mmol/L 3.32 (±1.2) 3.46 (±1.25) 3.23 (±1.18) 0.019
  HDL cholesterol, mmol/L 1.0 (0.8/1.2) 1.0 (0.8/1.2) 0.9 (0.8/1.2) 0.007
  WBC, Gpt/L 8.94 (7.0/11.7) 8.5 (6.79/10.56) 9.24 (7.13/12.28) ,0.001
  Hemoglobin, mmol/L 8.6 (±1.16) 8.8 (±1.0) 8.5 (±1.2) ,0.001
  CRP, mg/L 5.2 (5/15) 5.0 (5.0/9.1) 6.2 (5.0/20.2) ,0.001
Medication at hospital admission, n (%)
  DAP 227 (12.5) 84 (13.8) 143 (12.0) 0.540
  Aspirin 589 (35.6) 206 (33.8) 383 (32.0) 0.889
  Clopidogrel 81 (4.5) 31 (5.1) 50 (4.2) 0.553
  Beta-blocker 932 (51.5) 328 (53.9) 604 (50.3) 1.000
  ACEI 676 (37.4) 219 (36.0) 457 (38.1) 0.055
  ARB 206 (11.4) 75 (12.3) 132 (11.0) 0.739
  CCB 217 (12.0) 72 (11.8) 146 (12.2) 0.480
  Diuretic agents 566 (31.3) 163 (26.8) 403 (33.6) ,0.001
  Statins 608 (33.6) 230 (37.8) 378 (31.5) 0.088
  OAC 118 (6.5) 40 (6.6) 78 (6.5) 0.766
Medication at discharge, n (%)
  DAP 1623 (90.2) 571 (93.8) 1052 (87.7) 0.570
  Aspirin 33 (1.8) 14 (2.3) 19 (1.6) 0.369
  Clopidogrel 30 (1.7) 9 (1.5) 21 (1.8) 0.560
  Beta-blocker 1543 (85.3) 552 (90.6) 991 (82.6) 0.056
  ACEI 1371 (75.8) 470 (77.2) 901 (75.1) 0.180
  ARB 241 (13.3) 86 (14.1) 155 (13.0) 0.824
  CCB 207 (11.4) 69 (11.3) 138 (11.5) 0.641
  Diuretic agents 1009 (55.8) 293 (48.1) 716 (59.7) ,0.001
  Statins 1422 (78.6) 506 (83.1) 916 (76.3) 0.209
  OAC 96 (5.3) 33 (5.4) 63 (5.3) 0.885
Note: Values are percentages or mean ± SD, given in SI units.
Abbreviations: PCI, percutaneous coronary intervention; SAP, stable angina pectoris; UAP, unstable angina pectoris; nSTEMI, non-ST-segment elevation myocardial 
infarction; STEMI, ST-segment elevation myocardial infarction; LDL, low density lipoprotein; HDL, high density lipoprotein; GFR, glomerular filtration rate; WBC, white 
blood cell count; CRP, C-reactive protein; DAP, dual antiplatelet therapy; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium 
channel blocker; OAC, oral anticoagulation.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
695
Outcome comparison of DES versus BMSVascular Health and Risk Management 2011:7
mellitus (27.6% versus 38.6%, P , 0.001) and hypertension 
(69.3% versus 74.2%, P = 0.020) was significantly higher in 
patients treated with BMS, whereas a positive family history 
of CHD (30.0% versus 17.4%, P , 0.001), current   smoking 
(27.8% versus 20.2%, P , 0.001), and hyperlipidemia 
(40.9% versus 34.0%, P = 0.005) was found more often in 
patients treated with DES (Table 1).
The mean left ventricular ejection fraction was .50% 
in both groups; however, it was significantly lower in the 
BMS group (52% ± 16% BMS versus 56% ± 15% DES, 
P , 0.001) (Table 1).
Interestingly, the two groups did not differ significantly 
regarding the medication at admission to the hospital and at 
discharge, except for the use of diuretic agents, which were 
used more frequently in the BMS group.
Indication for hospital admission
A total of 258 (14.3%) patients suffered from stable angina, 
and 1517 (83.9%) suffered from acute coronary syndrome 
(unstable angina 510 [28.2%], NSTEMI 506 [28.0%], and 
STEMI 501 [27.7%]). In the DES group, the rate of stable 
angina was significantly higher than in the BMS group 
(19.9% versus 11.4%, P , 0.001). Unstable angina and 
STEMI were found more often in the BMS group, whereas 
NSTEMI did not differ between the two groups (Table 1).
Laboratory results
Markers of inflammation (C-reactive protein and white blood 
cell count) were slightly, but significantly different in the two 
groups (Table 1). Further prognostically relevant parameters,12,13 
ie, hemoglobin and LDL cholesterol, were within normal 
range in the group as a whole. Nevertheless, the mean value 
of these parameters was slightly higher in the DES group than 
in the BMS group. The glomerular   filtration rate, calculated 
via the Cockroft-Gault formula, was significantly decreased in 
the BMS group. Table 1 shows the details for these markers.
In-hospital adverse events
The median duration of hospital stay was 7 (4/11) days (DES 
6 [3/9] versus BMS 8 [6/12], P = 0.042). In-hospital cardiac 
(5.7% versus 0.5%, P = 0.035) and in-hospital noncardiac 
death (1.1% versus 0.2%, P , 0.001) occurred more fre-
quently in the BMS than in the DES group. The results were 
similar regarding incidence of myocardial infarctions (DES 
0.3% versus BMS 1.3%, P = 0.042). Bleeding complications 
were observed more frequently in the BMS cohort than in the 
DES cohort, especially gastrointestinal and minor bleedings.
Follow-up and survival analyses
Follow-up data concerning the primary endpoint of car-
diac death were obtained for 1730 patients (95.6%). The 
mean   follow-up was 34 ± 15 months. During follow-up, 
376 patients died of any causes (59 in the DES group [10.2%] 
and 317 in the BMS group [27.5%], P , 0.001). The inci-
dence of death of cardiac causes was 7.3% in the DES and 
19.6% in the BMS group (P , 0.001).
In addition, the incidence of stroke (3.1% versus 5.5%, 
P = 0.037) and coronary artery bypass surgery (DES 1.9% 
versus BMS 5.3%, P = 0.002) was lower in the DES group. 
The incidence of other adverse events during follow-up did 
not differ between the two groups (Table 2).
Kaplan-Meier analysis showed an increased cardiac mortal-
ity in the BMS group (Figure 1) (P , 0.001 via log-rank test). 
According to the multivariate model, including the classic risk 
factors and additional risk factors with prognostic relevance for 
progression of CHD, DES was not superior to BMS (hazard 
ratio [HR] 0.996, 95% confidence interval [CI] 0.455–2.182, 
P = 0.993) (Table 3). In this “fully adjusted model,” only glom-
erular filtration rate (GFR) was an independent predictor for 
cardiac mortality after PCI with stent implantation. Compared 
to a GFR . 90 mL/min, a GFR between 15 and 30 mL/min 
Table 2 Adverse events during follow-up
Variable N DES BMS P-value
Myocardial infarction  
(n = 1356)*
85 (6.3) 26 (5.1) 59 (7.0) 0.155
Stroke (n = 1381)* 63 (4.6) 16 (3.1) 47 (5.5) 0.037
ACB (n = 1378)* 55 (4.0) 10 (1.9) 45 (5.3) 0.002
Rehospitalization  
(n = 1340)*
429 (32.0) 156 (30.3) 273 (33.1) 0.285
Angiogram  
(n = 1339)*
325 (24.3) 125 (24.2) 200 (24.3) 0.975
PCI (n = 1375)* 205 (14.9) 70 (13.4) 135 (15.8) 0.222
Atrial fibrillation  
(n = 1379)*
121 (8.8) 40 (7.6) 81 (9.5) 0.248
Thrombosis 
(n = 1376)*
23 (1.7) 8 (1.5) 15 (1.8) 0.753
Bleeding events  
(n = 1378)*
39 (2.8) 14 (2.7) 25 (2.9) 0.796
Minor bleed 14 (1.0) 6 (1.1) 8 (0.9) 0.700
Groin hematoma 1 (0.1) 0 1 (0.1) 0.435
Groin bleed 13 (0.9) 5 (1.0) 8 (0.9) 0.965
Gastrointestinal bleed 6 (0.4) 3 (0.6) 3 (0.4) 0.540
Intracranial bleed 4 (0.3) 0 4 (0.5) 0.118
Embolism 1 (0.1) 0 1 (0.1) 0.435
Death (n = 1730)* 376 (21.7) 59 (10.2) 317 (27.5) ,0.001
Cardiac death 268 (15.5) 42 (7.3) 226 (19.6) ,0.001
Note: Variables are absolute number of events (percentages). 
Abbreviations: DES, drug-eluting stent; BMS, bare metal stent; ACB, aortocoronary 
bypass; PCI, percutaneous coronary intervention.
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about the long-term safety of these stents.9,10,14 Findings from 
various registries and meta-analyses showed an increase 
in all-cause mortality and the rate of major cardiovascular 
events9,15 after DES implantation as compared with BMS-
treated patients. The aim of the present study was to compare 
mortality in an unselected patient population undergoing PCI 
with DES versus BMS implantation.
As described in the results section, the two groups in 
part significantly differed concerning the prevalence of car-
diovascular risk factors (current smoking, diabetes mellitus, 
hypertension, hyperlipidemia, and positive family history). 
Also regarding the number of diseased vessels and the 
indication for PCI (ie, SAP, UAP, NSTEMI, and STEMI), 
significant differences can be observed. Patients presenting 
with SAP or UAP or 1-vessel-disease more often received 
DES, whereas patients suffering from STEMI or multivessel 
disease more often received BMS. These differences can be 
explained by the indications given in the revascularization 
guidelines.7 Meanwhile, current guidelines give a wider range 
of indications for the use of DES in more complex lesions 
and patient subsets.16
According to univariate analysis, DES are associated 
with an improved survival compared with BMS (P , 0.001) 
(Figure 1). However, in multivariate Cox regression analy-
ses that include classic risk factors and further prognostic 
variables, use of DES completely lost its prognostic value. 
Also hemoglobin level, age, diabetes mellitus, and left ven-
tricular ejection fraction, which are well known predictors 
for worse outcome of CHD patients, were not independently 
associated with the primary endpoint. In this model, the only 
independent predictor for cardiac mortality after PCI with 
stent implantation was impaired renal function. The authors 
conclude therefore that in a routine setting DES and BMS 
implantation are equally safe in terms of the occurrence of 
death of cardiac causes in the long term.
The findings of this present study are partly in line with 
recently published data on the safety of DES in the long and 
short term. Randomized studies taking diabetes mellitus, 
myocardial infarction, and multivessel disease as inclusion 
criteria17–21 show encouraging results for the use of DES in 
these patient populations.
In patients with impaired renal function, systemic 
changes such as chronic inflammation, oxidative stress, 
anemia, a procoagulative milieu and endothelial dysfunc-
tion promote the progression of atherosclerotic changes 
and therefore also count as cardiovascular risk factors.22–24 
Studies dealing with the impact of DES compared to BMS 
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Figure 1 Kaplan-Meier analysis for cardiac death, DES versus BMS.
Note: P , 0.001 by log rank test.
Abbreviations: DES, drug-eluting stent; BMS, bare-metal stent.
Table 3 Multivariate Cox regression analysis
HR Lower CI Upper CI P-value
DES 0.996 0.455 2.182 0.993
Diabetes mellitus 1.522 0.737 3.142 0.256
Family history 1.216 0.550 2.686 0.630
Current smoker 1.034 0.414 2.583 0.944
Male 1.247 0.536 2.900 0.608
Hypertension 1.050 0.442 2.491 0.912
Hyperlipidemia 1.348 0.570 3.187 0.496
Age 1.034 0.987 1.084 0.158
LDL cholesterol 1.037 0.798 1.443 0.642
CRP 1.001 0.993 1.010 0.787
Hb . Ref 0.551 0.267 1.140 0.108
LVEF . 50% 0.537 0.265 1.091 0.086
GFR 0.048
GFR , 15* 7.011 1.228 40.024 0.028
GFR 15–30* 6.788 1.406 32.764 0.017
GFR 30–60* 1.801 0.613 5.294 0.285
GFR 60–90* 1.190 0.454 3.118 0.723
Notes: *Compared to preserved renal function. Values in SI units.
Abbreviations:  HR,  hazard  ratio;  DES,  drug-eluting  stent;  LDL,  low  density 
lipoprotein CRP, C-reactive protein; Hb . Ref, hemoglobin above local level of 
normal; LVEF, left ventricular ejection fraction; GFR, glomerular filtration rate. 
increased the HR to 6.788 (95% CI 1.406–32.764, P = 0.017) 
and one of ,15 mL/min to 7.011 (95% CI 1.228–40.024, 
P , 0.028), respectively (see Table 3).
Discussion
After being introduced into daily clinical practice, the use of 
DES in PCI increased until several papers reported concerns 
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on the outcome in patients with renal impairment showed 
that the benefit of DES implantation depends on the degree 
of renal   impairment. Whereas patients with normal renal 
function or mildly impaired renal function (ie, creatinine 
clearance .60 mL/min and 40[30]–60 mL/min, respectively) 
profit from DES implantation,25–28 this advantage can no lon-
ger be seen in patients with moderate or severe renal impair-
ment (CrCl 15–30 mL/min and ,15 mL/min, respectively). 
The advantages for DES are mainly driven by a lower rate of 
revascularization (target vessel revascularization and target 
lesion revascularization), whereas no advantage concerning 
the occurrence of major adverse cardiac events, including 
cardiac death or death from any cause, was found. The fact 
that in this present study, impaired renal function was the 
only independent predictor in the multivariate model for 
worse outcome in patients after PCI with stent implanta-
tion emphasizes the influence of renal insufficiency on the 
progression of CHD (see Table 3).
Patients who suffer myocardial infarction (STEMI) com-
prise a high-mortality population. The use of stents is con-
sidered standard treatment in these patients.   Nevertheless, 
the use of DES under these circumstances is the subject 
of controversial discussion. Recently published results of 
randomized controlled trials included 300–700 patients 
and evaluated angiographic and clinical events 9 months 
and 12 months after PCI, respectively.19,20,29,30 Most of them 
concluded that DES is safe in STEMI and decreases the rate 
of re-interventions, but they did not find any advantage for 
DES concerning death or recurrent myocardial infarction. 
In contrast to these findings the results of observational 
studies which covered a follow-up period of 30 days up to 
2 years in “real-world” settings varied. They ranged from 
a significantly increased risk-adjusted mortality in patients 
treated with DES31 over comparable outcomes regarding 
long-term mortality32 to a lower risk-adjusted mortality 
for DES.33,34
Among the patients in this present study, 501   presented 
with acute myocardial infarction with ST-segment 
  elevation. Of them, 126 were treated with DES and 375 
with BMS. When applying univariate Kaplan-Meier 
analysis with log-rank test, DES was an independent factor 
concerning cardiac mortality (P = 0.005). In multivariate 
analysis including the abovementioned prognostically 
relevant factors, DES was no longer an independent fac-
tor (HR 0.114, 95% CI 0.007–1.805, P = 0.123; data not 
shown in the results   section). However, the use of DES in 
the “real-world” patient collective was not linked to poorer 
survival.
Conclusion
Treatment of patients with DES is safe in the long term, also 
in the subgroup of patients presenting with STEMI; however, 
it is not superior to BMS treatment.
Limitation
As this study represents the results of “real-life” practice, 
the choice of stent type was up to the interventional cardi-
ologist based on national and international guidelines and 
  recommendations. Thus, a limitation of this study is the 
smaller sample size of patients treated with DES in com-
parison to patients treated with BMS.
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